D. Almeida

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

This study evaluates the efficacy of ultrashort telacebec treatment in mouse models of Buruli ulcer, finding that total dose is more critical than duration and that resistance can emerge in immunocompromised hosts.

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

Manipulation of a cation-{Pi} sandwich reveals conformational flexibility in phenylalanine hydroxylase

This study shows that altering Phe80 in PAH affects its conformational equilibrium, revealing intermediates in the transition between resting and activated states.

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.

CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients

This study identifies CD44v6 expression as a predictor of therapy response and poor prognosis in gastric cancer patients, showing higher expression correlates with worse outcomes and benefit from chemotherapy.

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.